Faculty profile

Kolja Eppert

ResearcherPediatricsMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Kolja Eppert

Researcher

Pediatrics

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
3 publications in the last five years, latest in 2026.
Principal investigator on 6 research grants (5 CIHR, 1 NSERC), most recently in 2022.
Supervised 1 trainee who won CIHR awards, most recently in 2016.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Acute Myeloid Leukemia Stem Cell Biology Crc Drug Discovery Hematopoiesis Hematopoietic Stem Cell Pre-Leukemia Childhood Disease

Latest papers

A novel H2A-A127 variant is associated with human cancer and enhances tumor-related phenotypes in Drosophila melanogaster models.
Frontiers in oncology · 2026
Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.
Leukemia · 2025
Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia.
Leukemia research · 2024

All 15 publications

Latest funding

Identification of the mechanisms underlying the early stages of leukemogenesis in human hematopoietic stem cells.
CIHR · 2022 · Nominated PI
$898,876
Novel therapeutics to target leukemia stem cells
CIHR · 2017 · Nominated PI
$75,000
Canada Research Chair - Tier 2 - CIHR Funded
CIHR · 2017 · Nominated PI
$500,000

All 7 grants and awards

15 publications.

A novel H2A-A127 variant is associated with human cancer and enhances tumor-related phenotypes in Drosophila melanogaster models.

AlHajj Hassan Z, Dakik H, Arreba-Tutusaus P, Frey F, Mantash S, Mitchell A, Boileau M, Abelson S, Kleit M, Hayek Z, Awada J, El Darzi R, Eppert K, Shirinian M

Frontiers in oncology2026

DOI: 10.3389/fonc.2026.1814908 PMID: 42516136

Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.

Safa-Tahar-Henni S, Páez Martinez K, Gress V, Esparza N, Roques É, Bonnet-Magnaval F, Bilodeau M, Gagné V, Bresson E, Cardin S, El-Hachem N, Iasenza I, Alzial G, Boivin I, Nakamichi N, Soufflet AC, Mirela Pascariu C, Duchaine J, Mathien S, Bonneil É, Eppert K, Marinier A, Sauvageau G, Deblois G, Thibault P, Hébert J, Eaves CJ, Cellot S, Barabé F, Wilhelm BT

Leukemia2025

DOI: 10.1038/s41375-024-02400-w PMID: 39472547

Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia.

Brunetti M, Iasenza IA, Jenner AL, Raynal NJ, Eppert K, Craig M

Leukemia research2024

DOI: 10.1016/j.leukres.2024.107485 PMID: 38579483

CD200 expression marks leukemia stem cells in human AML.

Ho JM, Dobson SM, Voisin V, McLeod J, Kennedy JA, Mitchell A, Jin L, Eppert K, Bader G, Minden MD, Dick JE, Wang JCY

Blood advances2020

DOI: 10.1182/bloodadvances.2020001802 PMID: 33147339

Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.

Sharifi Z, Abdulkarim B, Meehan B, Rak J, Daniel P, Schmitt J, Lauzon N, Eppert K, Duncan HM, Petrecca K, Guiot MC, Jean-Claude B, Sabri S

Clinical cancer research : an official journal of the American Association for Cancer Research2019

DOI: 10.1158/1078-0432.ccr-19-0955 PMID: 31540977

Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness.

Boileau M, Shirinian M, Gayden T, Harutyunyan AS, Chen CCL, Mikael LG, Duncan HM, Neumann AL, Arreba-Tutusaus P, De Jay N, Zeinieh M, Rossokhata K, Zhang Y, Nikbakht H, Mouawad C, Massoud R, Frey F, Nasr R, El Cheikh J, El Sabban M, Kleinman CL, Mahfouz R, Minden MD, Jabado N, Bazarbachi A, Eppert K

Nature communications2019Senior author

DOI: 10.1038/s41467-019-10705-z PMID: 31253791

Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation.

Da Costa EM, Armaos G, McInnes G, Beaudry A, Moquin-Beaudry G, Bertrand-Lehouillier V, Caron M, Richer C, St-Onge P, Johnson JR, Krogan N, Sai Y, Downey M, Rafei M, Boileau M, Eppert K, Flores-Díaz E, Haman A, Hoang T, Sinnett D, Beauséjour C, McGraw S, Raynal NJ

Journal of experimental & clinical cancer research : CR2019

DOI: 10.1186/s13046-019-1242-8 PMID: 31196146

Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.

Laverdière I, Boileau M, Neumann AL, Frison H, Mitchell A, Ng SWK, Wang JCY, Minden MD, Eppert K

Blood cancer journal2018Senior author

DOI: 10.1038/s41408-018-0087-2 PMID: 29921955

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T

The Journal of clinical investigation2017

DOI: 10.1172/jci90825 PMID: 28481221

Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia.

Laverdière I, Boileau M, Herold T, Rak J, Berdel WE, Wörmann B, Hiddemann W, Spiekermann K, Bohlander SK, Eppert K

Experimental hematology2016Senior author

DOI: 10.1016/j.exphem.2016.07.012 PMID: 27473565

Something wrong or missing on this profile? Suggest a correction

Kolja Eppert

Research

Latest papers

Latest funding

A novel H2A-A127 variant is associated with human cancer and enhances tumor-related phenotypes in Drosophila melanogaster models.

Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.

Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia.

CD200 expression marks leukemia stem cells in human AML.

Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.

Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness.

Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation.

Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia.

Identification of the mechanisms underlying the early stages of leukemogenesis in human hematopoietic stem cells.

Novel therapeutics to target leukemia stem cells

Canada Research Chair - Tier 2 - CIHR Funded

Novel targeted therapeutics against leukemia stem cells

Homeostatic regulation of hematopoietic stem cells

Identification of bioactive molecules that target acute myeloid leukemia stem cells

CANADA RESEARCH CHAIRHOLDER - Tier 2 / TITULAIRE DE CHAIRE DE RECHERCHE DU CANADA - Niveau 2

Frequent collaborators

Janusz Rak

Nada Jabado

Kevin Petrecca

Guy Sauvageau

Gary Bader

Michael Downey

Trang Hoang

Mark Minden

Kevin Petrecca

Sonia Cellot

Moutih Rafei

Moutih Rafei

Morgan Craig

Morgan Craig

Stephanie Xie

Bertrand Jean-Claude